A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

[1]  S. Nikiforow,et al.  Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease , 2020, Bone Marrow Transplantation.

[2]  D. Fairlie,et al.  Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. , 2018, JCI insight.

[3]  P. Lai,et al.  Emerging role of C5a/C5aR IL-17A axis in cGVHD. , 2018, American journal of translational research.

[4]  P. Lai,et al.  Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg , 2017, Scientific Reports.

[5]  G. McDonald.  How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. , 2016, Blood.

[6]  Miguel Acevedo,et al.  Author , 2015, Real-Time Environmental Monitoring.

[7]  E. Volokhina,et al.  Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. , 2015, Blood.

[8]  R. Storb,et al.  Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial , 2015, Haematologica.

[9]  S. Vesely,et al.  The Role of Complement System in Graft versus Host Disease , 2015 .

[10]  M. Robin,et al.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  N. Burwick,et al.  Eculizumab fails to inhibit generation of C5a in vivo. , 2014, Blood.

[12]  P. Westervelt,et al.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. , 2014, Blood.

[13]  M. Pasquini,et al.  Acute graft-versus-host disease: a bench-to-bedside update. , 2014, Blood.

[14]  K. Tsai,et al.  Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD , 2014, Bone Marrow Transplantation.

[15]  R. Storb,et al.  Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation , 2014, Bone Marrow Transplantation.

[16]  P. Cravedi,et al.  Immune Cell‐Derived C3a and C5a Costimulate Human T Cell Alloimmunity , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  W. Drobyski,et al.  The Role of Regulatory T Cells in the Biology of Graft Versus Host Disease , 2013, Front. Immunol..

[18]  J. Janssen,et al.  Nutritional support in patients with GVHD of the digestive tract: state of the art , 2013, Bone Marrow Transplantation.

[19]  E. Shevach,et al.  Absent C3a and C5a receptor signaling into CD4+ T cells enables auto-inductive TGF-β1 signaling and induction of Foxp3+ T regulatory cells , 2012, Nature Immunology.

[20]  M. Merad,et al.  Antigen-presenting cell-derived complement modulates graft-versus-host disease. , 2012, The Journal of clinical investigation.

[21]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[22]  K. Takeuchi,et al.  The increased mucosal mRNA expressions of complement C3 and interleukin‐17 in inflammatory bowel disease , 2010, Clinical and experimental immunology.

[23]  A. Olson,et al.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.

[24]  E. Shpall,et al.  A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  W. Fridman,et al.  Prognostic Significance of Complement System Activation After Allogeneic Hematopoietic Stem Cell Transplantation. , 2009 .

[26]  P. Monk,et al.  Complement component 5a (C5a). , 2009, The international journal of biochemistry & cell biology.

[27]  M. Pasquini,et al.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.

[28]  P. Heeger,et al.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. , 2008, Blood.

[29]  C. Schworer,et al.  C4d staining is a valuable marker in identifying chronic GVHD in colonic biopsies following BMT , 2008, Bone Marrow Transplantation.

[30]  G. Dubyak,et al.  Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. , 2008, Immunity.

[31]  Y. Kanakura,et al.  Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody. , 2007 .

[32]  A. Higginbottom,et al.  The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding* , 2006, Journal of Biological Chemistry.

[33]  John D Lambris,et al.  Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.

[34]  Charles L Brooks,et al.  Albumin binding to FcRn: distinct from the FcRn-IgG interaction. , 2006, Biochemistry.

[35]  A. Valujskikh,et al.  Decay-accelerating factor modulates induction of T cell immunity , 2005, The Journal of experimental medicine.

[36]  Allen R. Chen,et al.  Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  D. Zahrieh,et al.  Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. , 2004, Blood.

[38]  H. Deeg,et al.  Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[40]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  B. Blazar,et al.  A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  A. Horwitz,et al.  Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn’s disease , 2000, Clinical and experimental immunology.

[43]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[44]  M. D. Williams,et al.  Gastrointestinal and nutritional sequelae of bone marrow transplantation. , 1996, Archives of disease in childhood.

[45]  S. Burdach,et al.  TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY: A Multicenter Phase III Study , 1995, Transplantation.

[46]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[47]  G. Füst,et al.  Clinical significance of longitudinal complement measurements in recipients of bone marrow transplant. , 1995, Bone marrow transplantation.

[48]  T. Halstensen,et al.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. , 1992, Gut.

[49]  B. Nilsson,et al.  Enhanced local production of complement components in the small intestines of patients with Crohn's disease. , 1990, The New England journal of medicine.

[50]  T. Halstensen,et al.  Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. , 1990, Gastroenterology.

[51]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[52]  W. Vogt,et al.  Incompatibility between Complement Components C3 and C5 of Guinea‐Pig and Man, an Indication of their Interaction in C5 Activation by Classical and Alternative C5 Convertases , 1979, Scandinavian journal of immunology.

[53]  H. Ochs,et al.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. , 1978, Blood.

[54]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.

[56]  K. Sullivan,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.

[57]  T. Hugli,et al.  Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. , 1984, Analytical biochemistry.

[58]  W. Vogt,et al.  A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. , 1978, Immunology.